Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives

키워드

참고문헌 (85)

1. GBD 2016 Mortality Collaborators, "Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016 : a systematic analysis for the Global Burden of Disease Study 2016", Lancet, 390, pp.1084~1150 (2017)
2. Mathers CD, "Projections of global mortality and burden of disease from 2002 to 2030", PLoS Med, 3, pp.e442~ (2006)
3. Ference BA, "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies : a consensus statement from the European Atherosclerosis Society Consensus Panel", Eur Heart J, 38, pp.2459~2472 (2017)
4. Cholesterol Treatment Trialists’ (CTT) Collaborators, "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27randomised trials", Lancet, 380, pp.581~590 (2012)
5. Jernberg T, "Cardiovascular risk in post-myocardial infarction patients : nationwide real world data demonstrate the importance of a long-term perspective", Eur Heart J, 36, pp.1163~1170 (2015)
6. Thompson PD, "Statin-associated side effects", J Am Coll Cardiol, 67, pp.2395~2410 (2016)
7. Abifadel M, "Mutations in PCSK9cause autosomal dominant hypercholesterolemia", Nat Genet, 34, pp.154~156 (2003)
8. Cohen JC, "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease", N Engl J Med, 354, pp.1264~1272 (2006)
9. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
10. Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
11. Taylor BA, "Statins and their effect on PCSK9-impact and clinical relevance", Curr Atheroscler Rep, 18, pp.46~ (2016)
12. Shapiro MD, "From lipids to inflammation : new approaches to reducing atherosclerotic risk", Circ Res, 118, pp.732~749 (2016)
13. Landlinger C, "The AT04A vaccine against proprotein convertase subtilisin", kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden. CETP mice, 2017, pp.38, 2499~2507
14. Blom DJ, "A 52-week placebo-controlled trial of evolocumab in hyperlipidemia", N Engl J Med, 370, pp.1809~1819 (2014)
15. Koren MJ, "Anti-PCSK9monotherapy for hypercholesterolemia : the MENDEL-2randomized, controlled phase III clinical trial of evolocumab", J Am Coll Cardiol, 63, pp.2531~2540 (2014)
16. Robinson JG, "Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia : the LAPLACE-2 randomized clinical trial", JAMA, 311, pp.1870~1882 (2014)
17. Stroes E, "Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance : the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab", J Am Coll Cardiol, 63, pp.2541~2548 (2014)
18. Raal FJ, "Inhibition of PCSK9with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial", Lancet, 385, pp.341~350 (2015)
19. Raal FJ, "PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial", Lancet, 385, pp.331~340 (2015)
20. Sabatine MS, "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1500~1509 (2015)
21. Kiyosue A, "A phase 3 study of evolocumab(AMG 145)in statin-treated japanese patients at high cardiovascular risk", Am J Cardiol, 117, pp.40~47 (2016)
22. Nissen SE, "Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance : the GAUSS-3 randomized clinical trial", JAMA, 315, pp.1580~1590 (2016)
23. Lagace TA, "Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice", J Clin Invest, 116, pp.2995~3005 (2006)
24. Bays H, "Alirocumab as add-on to atorvastatin versus other lipid treatment strategies : ODYSSEY OPTIONS I randomized trial", J Clin Endocrinol Metab, 100, pp.3140~3148 (2015)
25. Kastelein JJ, "ODYSSEY FH I and FH II : 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia", Eur Heart J, 36, pp.2996~3003 (2015)
26. Kereiakes DJ, "Efficacy and safety of the proprotein convertase subtilisin", kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy : the ODYSSEY COMBO I study, 2015, pp.169, 906~915
27. Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)
28. Roth EM, "ODYSSEY MONO : effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks", Future Cardiol, 11, pp.27~37 (2015)
29. Farnier M, "Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial", Atherosclerosis, 244, pp.138~146 (2016)
30. Ginsberg HN, "Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg", dl or higher, 2016, pp.30, 473~483
31. Roth EM, "A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I", Atherosclerosis, 254, pp.254~262 (2016)
32. Stroes E, "Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy : the ODYSSEY CHOICE II study", J Am Heart Assoc, 5, pp.e003421~ (2016)
33. El Shahawy M, "Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II)", Am J Cardiol, 120, pp.931~939 (2017)
34. Qamar A, "Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab : an analysis of FOURIER Trial Data", JAMA Cardiol, 4, pp.59~63 (2019)
35. Karatasakis A, "Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia : a meta-analysis of 35 randomized controlled trials", J Am Heart Assoc, 6, pp.e006910~ (2017)
36. Wiviott SD, "Effect of evolocumab on type and size of subsequent myocardial infarction : a prespecified analysis of the FOURIER randomized clinical trial", JAMA Cardiol, 5, pp.787~793 (2020)
37. Giugliano RP, "Stroke prevention with the PCSK9(proprotein convertase subtilisin-kexin type 9)inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis", Stroke, 51, pp.1546~1554 (2020)
38. Jukema JW, "Effect of alirocumab on stroke in ODYSSEY OUTCOMES", Circulation, 140, pp.2054~2062 (2019)
39. Du H, "Proprotein convertase subtilisin", kexin 9 inhibitors in reducing cardiovascular outcomes : a systematic review and meta-analysis, 2019, pp.105, 1149~1159
40. Gencer B, "Lipoprotein(a) : the revenant", Eur Heart J, 38, pp.1553~1560 (2017)
41. Willeit P, "Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials", Lancet, 392, pp.1311~1320 (2018)
42. Cao YX, "A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein(a)levels", Am J Cardiovasc Drugs, 19, pp.87~97 (2019)
43. O’Donoghue ML, "Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk", Circulation, 139, pp.1483~1492 (2019)
44. Reyes-Soffer G, "Effects of PCSK9inhibition with alirocumab on lipoprotein metabolism in healthy humans", Circulation, 135, pp.352~362 (2017)
45. Watts GF, "Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a)particle kinetics", Eur Heart J, 39, pp.2577~2585 (2018)
46. Edmiston JB, "Discordant response of low-density lipoprotein cholesterol and lipoprotein(a)levels to monoclonal antibodies targeting proprotein convertase subtilisin", kexin type 9, 2017, pp.11, 667~673
47. Shapiro MD, "Relationship between low-density lipoprotein cholesterol and lipoprotein(a)lowering in response to PCSK9 inhibition with evolocumab", J Am Heart Assoc, 8, pp.e010932~ (2019)
48. Tang Z, "PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages", Int J Mol Med, 30, pp.931~938 (2012)
49. Ferri N, "Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels", Atherosclerosis, 220, pp.381~386 (2012)
50. Ding Z, "Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta", Antioxid Redox Signal, 22, pp.760~771 (2015)
51. Ding Z, "Cross-talk between LOX-1 and PCSK9 in vascular tissues", Cardiovasc Res, 107, pp.556~567 (2015)
52. Tang ZH, "New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4", NF-κB pathway, 2017, pp.262, 113~122
53. Kuhnast S, "Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin", J Lipid Res, 55, pp.2103~2112 (2014)
54. Muldoon MF, "Effects of lovastatin on cognitive function and psychological well-being", Am J Med, 108, pp.538~546 (2000)
55. Muldoon MF, "Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults", Am J Med, 117, pp.823~829 (2004)
56. Navarese EP, "Effects of proprotein convertase subtilisin", kexin type 9 antibodies in adults with hypercholesterolemia : a systematic review and meta-analysis, 2015, pp.163, 40~51
57. Toth PP, "Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies", Circulation, 135, pp.1819~1831 (2017)
58. Giugliano RP, "Cognitive function in a randomized trial of evolocumab", N Engl J Med, 377, pp.633~643 (2017)
59. Harvey PD, "No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials : a meta-analysis of individual patient data", Eur Heart J, 39, pp.374~381 (2018)
60. Foltz IN, "Evolution and emergence of therapeutic monoclonal antibodies : what cardiologists need to know", Circulation, 127, pp.2222~2230 (2013)
61. Ridker PM, "Lipid-reduction variability and antidrug-antibody formation with bococizumab", N Engl J Med, 376, pp.1517~1526 (2017)
62. Koren MJ, "Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia : results up to 4 years from the open-label OSLER-1 extension study", JAMA Cardiol, 2, pp.598~607 (2017)
63. Farnier M, "Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia : an open-label extension of the ODYSSEY program", Atherosclerosis, 278, pp.307~314 (2018)
64. Blom DJ, "Effects of evolocumab on vitamin e and steroid hormone levels : results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study", Circ Res, 117, pp.731~741 (2015)
65. Arrieta A, "Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers : insights derived from the FOURIER trial", JAMA Cardiol, 2, pp.1369~1374 (2017)
66. Kazi DS, "Cost-effectiveness of alirocumab : a just-in-time analysis based on the ODYSSEY outcomes trial", Ann Intern Med, 170, pp.221~229 (2019)
67. Kaufman TM, "Application of PCSK9 inhibitors in practice", Circ Res, 124, pp.32~37 (2019)
68. Knickelbine T, "A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice", J Clin Lipidol, 13, pp.265~271 (2019)
69. Reynolds VW, "Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates", J Clin Lipidol, 13, pp.254~264 (2019)
70. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
71. Birmingham BK, "Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States", Eur J Clin Pharmacol, 71, pp.329~340 (2015)
72. Li YF, "The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque : a meta-analysis report", BMC Cardiovasc Disord, 15, pp.6~ (2015)
73. Wang C, "Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations", Br J Clin Pharmacol, 85, pp.114~125 (2019)
74. Han Y, "ODYSSEY EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand", J Clin Lipidol, 14, pp.98~108 (2020)
75. Koh KK, "A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)", J Clin Lipidol, 12, pp.162~172 (2018)
76. 이은정, "2018 Guidelines for the management of dyslipidemia", The Korean Journal of Internal Medicine, 34(4), pp.723~771 (2019), 대한내과학회[DOI]
77. Mach F, "2019 ESC", EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
78. Schwartz GG, "Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial", JAMA, 285, pp.1711~1718 (2001)
79. Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes", N Engl J Med, 350, pp.1495~1504 (2004)
80. Koskinas KC, "Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)", J Am Coll Cardiol, 74, pp.2452~2462 (2019)
81. Ray KK, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol", N Engl J Med, 376, pp.1430~1440 (2017)
82. Pan Y, "A therapeutic peptide vaccine against PCSK9", Sci Rep, 7, pp.12534~ (2017)
83. Kawakami R, "Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin", kexin type 9 (PCSK9) epitope in mice, 2018, pp.13, e0191895~
84. Momtazi-Borojeni AA, "Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system", Atherosclerosis, 283, pp.69~78 (2019)
85. Rymer JA, "Use of low-density lipoprotein-lowering therapies before and after PCSK9inhibitor initiation", J Am Heart Assoc, 9, pp.e014347~ (2020)

관련 논문AI추천